New horizons for GAG therapy in the management of urothelial damage.
Urothelial defects may manifest as various types of signs of symptoms such as frequency and urgency, haematuria and pain. Both prevention and treatment of urothelial damage is fundamental. Many currently adopted treatments lack robust clinical data and are associated with variability in management strategies. Glycosoaminoglycan (GAG) therapy is one of the most promising therapies in treatment of chemotherapy and radiotherapy-induced urothelium defects, and has been investigated in both animal models and clinical studies.
Department of Urology, Istituto Clinico Humanitas, Humanitas Clinical and Research Center, Rozzano (Milan) - Italy.
Massimo
M
Lazzeri
D000970:Antineoplastic Agents / Q000009:adverse effects*; D003556:Cystitis / Q000188:drug therapy* / Q000209:etiology*; D006025:Glycosaminoglycans / Q000627:therapeutic use*; D006801:Humans; D011832:Radiation Injuries / Q000188:drug therapy* / Q000209:etiology*; D011878:Radiotherapy / Q000009:adverse effects; D019459:Urothelium / Q000187:drug effects / Q000528:radiation effects
D000970:Antineoplastic Agents; D006025:Glycosaminoglycans